Asian journal of urology · 2017 · 30 citations · 13 references
MedicineOncologyPharmacologyChemotherapyMedical OncologyUrologic OncologyAndrogen Deprivation TherapyGenitourinary Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyMetastatic Disease TreatmentProstate CancerCastration-resistant Prostate Cancer TherapyEastern Cooperative Oncology Group Performance StatusMetastatic Castration-resistant Prostate CancerPlacebo-controlled Efficacy AssessmentProstate AdenocarcinomaProstate Cancer Hormonal TherapyProstatic AdenocarcinomaTestosterone Therapy
This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients from China, Malaysia, Thailand and Russia. Adult chemotherapy-naïve patients with confirmed prostate adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) grade 0–1, ongoing androgen deprivation (serum testosterone <50 ng/dL) with prostate specific antigen (PSA) or radiographic progression were randomized to receive abiraterone acetate (1000 mg, QD) + prednisone (5 mg, BID) or placebo + prednisone (5 mg, BID), until disease progression, unacceptable toxicity or consent withdrawal. Primary endpoint was improvements in time to PSA progression (TTPP). Totally, 313 patients were randomized (abiraterone: n = 157; prednisone: n = 156); and baseline characteristics were balanced. At clinical cut-off (median follow-up time: 3.9 months), 80% patients received treatment (abiraterone: n = 138, prednisone: n = 112). Median time to PSA progression was not reached with abiraterone versus 3.8 months for prednisone, attaining 58% reduction in PSA progression risk (HR = 0.418; p < 0.0001). Abiraterone-treated patients had higher confirmed PSA response rate (50% vs. 21%; relative odds = 2.4; p < 0.0001) and were 5 times more likely to achieve radiographic response than prednisone-treated patients (22.9% vs. 4.8%, p = 0.0369). Median survival was not reached. Most common (≥10% abiraterone vs. prednisone-treated) adverse events: bone pain (7% vs. 14%), pain in extremity (6% vs. 12%), arthralgia (10% vs. 8%), back pain (7% vs. 11%), and hypertension (15% vs. 14%). Interim analysis confirmed favorable benefit-to-risk ratio of abiraterone in chemotherapy-naïve men with mCRPC, consistent with global study, thus supporting use of abiraterone in this patient population.
13
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan, Matthew R. Smith, Johann S. de Bono et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Karim Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology · 2012 · 1.4K citations
Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations
Philip W. Kantoff, Thomas Schuetz, Brent A. Blumenstein et al. · Journal of Clinical Oncology · 2010 · 973 citations
Medicine, Immunology, Oncology +17